Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

ofatumumab

ofatumumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Kesimpta INJECTION, SUBCUTANEOUS 20 mg/0.4 mL      
Arzerra SOLUTION, INTRAVENOUS 20 mg/mL      
VIEW MORE Antineoplastic Agents
CLASS
100000
Comments:

At Huntsville Main/W&C/Madison, orders for this medication should be rejected and reviewed by an oncology clinical specialist or an oncology pool member (see second page of the document "Hormone Therapies and Guidance on Oral Chemotherapy") 

Arzerra: Restricted to Oncology.  Not routinely stocked: any need for the drug in the hospital will be planned ahead, and it can be ordered in advance.

 

Kesimpta:  Inpatients may use home supply.

 

Reviewed: April 27, 2010, Oct. 2022 (Kesimpta)

Last updated: Mar. 5, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved